<DOC>
	<DOCNO>NCT01663233</DOCNO>
	<brief_summary>This study ass whether LCZ696 use combination amlodipine provide great BP lower benefit compare amlodipine alone Asian hypertensive patient adequately responsive amlodipine therapy .</brief_summary>
	<brief_title>Efficacy Safety LCZ696 200 mg + Amlodipine 5 mg Comparison With Amlodipine 5 mg Hypertensive Patients Not Responding Amlodipine</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<mesh_term>LCZ 696</mesh_term>
	<criteria>Patients must give write informed consent diagnosis hypertension : Untreated patient must msSBP ≥ 150 mmHg &lt; 180 mmHg Visit 1 Visit 101 . Pretreated patient must msSBP ≥ 145 mmHg &lt; 180 mmHg wash Visit 101 . All patient must office msSBP ≥ 145 mmHg &lt; 180 mmHg completion 4week runin epoch ( randomization visit ( Visit 201 ) . Patients must successfully complete ABPM pas technical requirement Visit 201 . Malignant severe hypertension ( grade 3 WHO classification ; msDBP ≥110 mmHg and/or msSBP ≥ 180 mmHg ) . History angioedema , drugrelated otherwise . History evidence secondary form hypertension . Transient ischemic cerebral attack ( TIA ) 12 month prior Visit 1 history stroke . History myocardial infarction , coronary bypass surgery PCI 12 month prior Visit 1 Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Essential hypertension</keyword>
	<keyword>High blood pressure</keyword>
</DOC>